Notably, pathway enrichment analysis revealed that these candidate compounds target key oncogenic pathways, including JAK-STAT and PD-L1 signaling, which are functionally aligned with MCMBP-associated processes, thereby reinforcing the potential of these drugs to counteract MCMBP-driven tumor progression. This evidence concerns the gene MCMBP and neoplasm.